New & Exciting at TUC

News items updated

SoLa therapy involves a device that Dr Butrick was involved in its development for the treatment of nearly all forms of chronic pelvic pain.  The series of office based therapies that take less than 5 minutes to preform are resulting in amazing outcomes.  Patients unable to have sex, exercise or even sit in a chair are returning to a normal life.  With over 100 patients treated, 80% are showing more than 35% improvement and 1/3rd have experienced resolution of their pain.  Interstitial cystitis, vulvodynia and endometriosis pain symptoms are responding to this form of photobiomodulation.  Most patients have failed other forms of therapy yet their response to this new therapy is truly life changing. Call now to see if you can take advantage of the newest therapy for pelvic floor pain.  Visit

Photobiomodulation is coming to TUC. The newest therapy for pelvic floor pain will soon be offered at The Urogynecology Center. We will begin treating patients on June 21, 2019. We will be the first office involved in a multi-center trial using this new therapy for chronic myofascial pain. This is extremely exciting and will likely change how we manage chronic pelvic pain.

  • Dr. B. did a round table discussion “meet the experts“ at the 2015 annual AUGS meeting on the management of mesh complications.
  • Dr. B. was asked to do an entire workshop on the management of transvaginal mesh related complications at the combined meetings of AUGS and the International Continence Society in 2014.
  • Dr. B. presented his data concerning the use of intraoperative neurodiagnostics during the placement of InterStim. His success rate in the last 10 years of 94% amazed many of the attendees at the annual Society of urodynamics and female urology meeting in 2016
  • Dr. B. has been asked to be the key speaker at the Seattle gynecologic Society in September 2016. He has been asked to discuss topics to include chronic pelvic pain, persistent postoperative pain and painful bladder syndrome/interstitial cystitis.
  • Dr. B. has been asked to do to round table discussions “meet the experts” for the upcoming 2016 annual AUGS meeting. The topics he has been asked to discuss includes neurodiagnostic testing during the placement of InterStim and persistence of postoperative pain-identification and prevention.
  • Dr. B. has had his article concerning persistent postoperative pain published in the Journal of Female Pelvic Medicine and Reconstructive Surgery. It was so well received they are planning on a podcast so that this ground breaking information can be more widely disseminated. Click here to read the article!
  • TUC is involved in two research studies for the management of various types of pelvic pain. 1 involves the treatment of interstitial cystitis and the other involves a new therapeutic option for pelvic floor myofascial pain disorders.

Our mission at the Urogynecology Center is to provide the highest level of care possible for women with incontinence, pelvic pain and/or pelvic organ prolapse. We provide this care in an individualized and highly compassionate manner, always keeping the needs of the patient in the forefront.

Request a Consultation

  • This field is for validation purposes and should be left unchanged.

Latest News

Seminar – November 2019

Dr. Butrick is holding a free seminar on urinary and fecal incontinence, pelvic organ prolapse, bladder infections, & pelvic pain disorders. The talk will include a new cold laser therapy called Sola Therapy which is a break through in the management of chronic pelvic pain. The seminar will be held at 12200 W. 106th St., ... read more

Master Surgeon – 2019

Dr. Butrick became an accredited Master Surgeon in Minimally Invasive Surgery. This accreditation demonstrates Dr. Butrick's  commitment and ability as a surgeon to consistently deliver the highest level of care possible and signifies that Dr. Butrick is among the best in his specialty.

Axionics – 2019

Dr. Butrick attended a meeting to provide input on a new device for sacral nerve stimulation from Axionics. This new device greatly reduces the size of a neuromodulation device battery to the approximate size of a quarter.